Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Gustavo Dos Santos FernandesDaniel M GirardiJoão Paulo G BernardesFelipe P FonsecaEduardo R FregnaniPublished in: BMC cancer (2018)
This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.